Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728722 | 0.87 | GPR119 (0.43) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL3695891 | 0.87 | GPR119 (0.45) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2728849 | 0.87 | GPR119 (0.45) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL3695130 | 0.87 | GPR119 (0.45) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2729242 | 0.79 | GPR119 (0.42) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL2728715 | 0.79 | GPR119 (0.42) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL2730262 | 0.77 | GPR119 (0.47) | GPR119 | |
| SCHEMBL2730665 | 0.76 | GPR119 (0.45) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2728865 | 0.75 | GPR119 (0.43) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2730165 | 0.75 | GPR119 (0.43) | GPR119GPR183CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | claimed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | claimed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | claimed |
| EP-2445904-A1 | NOVEL GPR 119 AGONISTS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | claimed |
| WO-2010146605-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-23 | — | — | WO | claimed |
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | disclosed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | disclosed |
| EP-2209780-A2 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF- KAPPA B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009058944-A2 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND /OR NF- KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR4, GPR39 | GPR119 1/4885GPR183 22/4885CYP3A4 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.